Azathioprine vs MMF for new autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This test compares two medicines—azathioprine and mycophenolate mofetil (MMF)—to see which is better at putting autoimmune hepatitis into remission without using steroids first. It is for people who have just been diagnosed and haven't started treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of autoimmune hepatitis (AIH) based on a liver biopsy and blood tests showing inflammation.
- You have never taken immune-suppressing medications like steroids, azathioprine, or MMF to treat your AIH.
- You do not have another liver disease like hepatitis B, C, primary biliary cholangitis, or alcohol-related liver damage.
- Your blood cell counts (platelets and white blood cells) are not too low, and you are not pregnant or breastfeeding.
- You are willing to sign a consent form and follow the study visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at factors that help predict how well people with autoimmune hepatitis respond to treatment. It is for patients who are newly diagnosed or have not had treatment for at least 3 months, and who have had a liver biopsy to confirm the diagnosis.
This trial tests a new medication called inebilizumab for people with autoimmune hepatitis (a condition where the body's immune system attacks the liver) who haven't responded well to standard treatments or can't tolerate them. The study aims to see if this new drug can help control liver inflammation and reduce the need for high-dose steroids.
This trial tests a drug called belimumab for people with autoimmune hepatitis that is not well controlled. It aims to see if adding belimumab to your current treatment can help reduce liver inflammation.
This trial tests whether a procedure called therapeutic plasma exchange (TPE) — which cleans harmful substances from your blood — is more effective than standard medicines for treating severe autoimmune hepatitis. It may be an option if your condition is very serious and you are not able to get a liver transplant within the next month.
This study examines the molecular profile of autoimmune hepatitis (a liver condition where the immune system attacks liver cells) using lipid analysis. Researchers hope to better understand the disease and potentially improve diagnosis and treatment in the future.
This study is looking at specific immune cells (T cells) in the blood of people with autoimmune hepatitis (AIH) to better understand the disease. If you have untreated AIH and meet certain criteria, you may be able to participate.
Hear when a new Autoimmune Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.